Combined modality therapy is a standard therapy for patients with unresectable stage III non-small cell lung cancer (NSCLC). Gefitinib is active in advanced NSCLC, and in preclinical models, it potentiates the activity of radiation therapy. We investigate the tolerability of gefitinib in combined modality therapy in combination with three-dimensional thoracic conformal radiation therapy (3-dimensional TCRT). Methods: Stage III patients with a good performance status were treated with induction chemotherapy (carboplatin area under the curve [AUC] of 5, irinotecan 100 mg/m 2 , and paclitaxel 175 mg/m
L
ung cancer is the leading cause of cancer-related deaths in the United States, and in 2007 it is estimated that more people died from lung cancer than prostate, colorectal, and breast cancer combined. 1 Eighty-five percent of the cases of lung cancer are non-small cell lung cancer histology (NSCLC), and 30 to 45% will be stage IIIA or B at the time of diagnosis, and are considered potentially curable. 2, 3 In the United States, the standard of care for patients with a good performance status is the combination of systemic dose chemotherapy and thoracic radiation therapy, often referred to as combined modality therapy. 4 Unfortunately, the majority of patients treated with combined modality therapy experience locoregional or distant (or both) progression of their disease. We have previously reported a phase I/II dose escalation incorporating 3-dimensional thoracic conformal radiation therapy (3-dimensional TCRT) into the treatment paradigm of induction and concurrent carboplatin and paclitaxel. 5 In this trial, we successfully escalated the dose of 3-dimensional TCRT from 60 to 74 Gy in 62 patients with unresectable stage III NSCLC with an acceptable rate of acute and late toxicities. The primary acute toxicity was esophagitis, but only 8% of patients experienced grade 3 or 4 esophagitis. The overall survival observed on this trial was encouraging, and the median survival time was 25 months, and the 1-, 3-, 5-year survival rates with 95% confidence intervals (CI) were 71% (60 -80%), 39% (27%-51%), and 26% (15%-38%), respectively. 6 Despite the more aggressive locoregional treatment, at least 35% of patients experienced locoregional failures. A separate analysis of prognostic factors of patients treated on our dose escalation trials revealed that the postinduction chemotherapy gross tumor volume (GTV) was predictive of survival. 7 This observation provided the rationale that a more aggressive induction chemotherapy treatment may reduce the intrathoracic tumor volume before initiating the chemoradiotherapy and improve locoregional control and survival. Our subsequent stage III trial was a phase I trial investigating further dose escalation of 3-dimensional TCRT. 8 On this trial, we incorporated induction chemotherapy with carboplatin, paclitaxel, and irinotecan (CIP) with growth colony stimulating factor for two cycles, which we had previously investigated in advanced disease. 9, 10 The induction therapy with growth colony stimulating factor support was well tolerated, and the rate of all toxicities was less than 10%, and only 8% of cycles were complicated by grade 3 or 4 neutropenia.
At the time this trial was developed, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), had revealed promising activity in phase II trials in patients with advanced NSCLC who had progressed after one or two therapies. 11, 12 Two large phase III trials using carboplatin/paclitaxel and cisplatin/gemcitabine with and without gefitinib had been completed, but the survival results were not available. 9, 10 Gefitinib appeared to be a promising agent for the treatment of advanced stage disease, and preclinical data indicated that the gefitinib may potentiate the activity of radiation therapy. [13] [14] [15] [16] Given the safety and tolerability data from our previous trials, the combination of induction chemotherapy with CIP, and concurrent chemotherapy with weekly carboplatin and paclitaxel with 3-dimensional TCRT to 74 Gy appeared to be an appropriate treatment paradigm to investigate gefitinib in the treatment of unresectable stage III disease.
PATIENTS AND METHODS

Eligibility
Patients eligible for this trial were required to have a cytologic or histologic diagnosis of stage IIIA or IIIB disease and be deemed appropriate candidates for combined modality therapy. All patients were reviewed by a thoracic radiologist, pulmonologist, thoracic surgeon, radiation oncologist, and medical oncologist. Initial staging consisted of a chest radiograph and a staging chest computed tomography (CT) scan, which included full visualization of the liver and adrenal glands. Radionuclide bone scans and/or positron emission tomography (PET) scans were required as was either a CT or magnetic resonance imaging scan of the brain. Patients with supraclavicular adenopathy, superior sulcus tumors, or pleural effusion were excluded. Patients were required to have Eastern Cooperative Oncology Group performance status of 0 or 1 and could not have received prior chemotherapy or radiotherapy to the chest. Other required parameters were as follows: absolute neutrophil count (ANC) Ն1500/mm 3 , platelet count Ն100,000/mm 3 , serum creatinine Ͻ1.6 mg/dL or Cockcroft calculated creatinine clearance Ͼ40 mL/min, serum bilirubin Յ1.5 times upper limit of institutional normal, serum aspartate aminotransferase and alanine aminotransferase Յ2.5 times upper limit of institutional normal. Pulmonary function tests were required to document a forced expiratory volume 1 second of Ͼ800 mL. Subjects taking phenytoin, rifampin, barbiturates, carbamazepine, and St. John's Wort and patients with a prior malignancy who were disease free Ͻ5 years were excluded (except carcinoma in situ of the cervix or breast and nonmelanomatous skin cancer). Of note, there was not an inclusion or exclusion criteria related to weight loss. Patients underwent a bronchoscopy, mediastinoscopy, or transthoracic fine-needle aspiration for diagnosis and staging as clinically indicated. This trial was approved by the Protocol Review Committee of the Lineberger Comprehensive Cancer Center (LCCC) and the Institutional Review Board of the University of North Carolina School of Medicine and labeled LCCC 0215. All patients provided informed consent before enrollment on this trial.
Treatment Administration
Patients entered onto this trial received induction chemotherapy with carboplatin area under the concentration curve (AUC) of 5 by intravenous (IV) infusion using the Calvert Equation, 17 irinotecan 100 mg/m 2 IV infusion, and paclitaxel 175 mg/m 2 IV infusion, all given on day 1 and 22. Patients received pegfilgrastim 6 mg on the day 2 and 23 of induction chemotherapy. Details of this regimen have been published previously. 18, 19 On day 43, patients received 7 or 8 weekly treatments of paclitaxel 45 mg/m 2 /wk over 1 hour, carboplatin AUC 2, and gefitinib 250 mg orally daily with concurrent with TCRT. Treatment on days 22 and 43 required an ANC of at least 1500/mm 3 and platelets of at least 100,000/ mm 3 . A complete blood count was monitored weekly during concurrent chemoradiotherapy. The carboplatin dose was reduced to an AUC of 1 if the ANC was Ͻ1000/mm 3 but greater than 500/mm 3 or the platelets were Ͻ75,000/mm 3 . Both paclitaxel and carboplatin were held if the ANC was Ͻ500/mm 3 or the platelets were Ͻ50,000/mm 3 . In the initial protocol, patients continued to receive gefitinib 250 mg daily for 2 years or until disease progression or unacceptable toxicity. The trial was amended after an interim analysis of Southwest Oncology Group (SWOG) trial 0023 by Data and Safety Committee of the SWOG revealed that the addition of gefitinib after completion of chemoradiotherapy in stage III disease did not improve survival. 20 The gefitinib was discontinued after completion of TCRT, but was continued during the TCRT.
TCRT was initiated on day 43 concurrent with weekly paclitaxel, carboplatin, and gefitinib as noted above. Patients underwent a planning CT after the second cycle of chemotherapy. The initial clinical target volume (CTV I ) was defined as the prechemotherapy primary tumor volume, clinically positive lymph nodes and the bilateral (elective) mediastinum. Clinically positive lymph nodes were defined as nodes Ն1 cm in greatest diameter visualized on CT scan, mediastinoscopy-positive or lymph nodes that were Ͻ1 cm and positive on PET scan were included in the CTV 1 . The PET scan was not used in the target volume delineation. The elective mediastinum was defined as the mediastinum 0.5 to 2.0 cm below the clavicular heads to 1.0 to 2.0 cm below the carina or lowest clinically positive lymph nodes. The boost clinical target volume (CTV B ) was defined as the postinduction chemotherapy primary tumor and clinically positive lymph node regions involved initially. The initial treatment to the CTV I was performed using AP/PA (anteroposterior/posteroanterior) fields. The CTV I received a dose of 44 Gy with a 1.0 to 2.0 cm margin to account for subject motion, registration inaccuracies, set-up variation, and dose build-up. The total dose delivered to the CTV I was determined by a spinal cord tolerance of 4750 cGy maximum. The boost treatment was accomplished with oblique fields off cord with a minimum of two beams. The off-cord boost received doses of 74 Gy to the CTV B with a 1.0 to 2.0 cm margin. Patients received 2 Gy/d Monday through Friday with the exception of holidays with Ն6 MV photons. Dose limits for normal tissue were as follows: no more than 35% of the lung volume could receive Ͼ20 Gy (V 20 ), no part of the spinal cord could receive Ͼ50 Gy, and no part of the brachial plexus could receive Ͼ66 Gy. The V 20 was calculated using the total lung volume defined as total lung minus the GTV. There were no required dose limits on the treatment for the heart and the esophagus; however, it was recommended that the entire heart (and/or left ventricle) not receive Ͼ60 Gy, and the full circumference of the esophagus not receive Ͼ60 Gy for 6 cm. Heterogeneity corrections were required in the treatment planning. Patients did not receive intensity modulate radiotherapy on this trial.
Response and Toxicity Evaluation
The response rate after two cycles of induction CIP was assessed during week 6 of treatment with a staging chest CT scan. All patients had a CT scan performed 2 months after the last dose of TCRT were followed clinically every 2 months with chest radiographs for the first 2 years. If patients had signs on physical examination (eg, palpable lymphadenopathy) or symptoms concerning for disease progression patients underwent the additional testing including repeat CT scans of the chest/abdomen, imaging of the brain, and bone scans as clinically indicated. The date of progression was defined as the date there was evidence of progression of disease on physical examination or radiographic imaging. Responses were assessed by standard World Health Organization criteria. 21 Toxicity was assessed using the Common Toxicity Criteria scale version 2.0. The primary dose-limiting toxicity was defined as grade 4 esophagitis.
Study Design and Statistical Design
The primary objective was to assess the toxicity and tolerability of the combination of induction CIP with pegfilgrastim supportive therapy, followed by concurrent carboplatin, paclitaxel, and gefitinib with high dose 3-dimensional TCRT in unresectable stage IIIA or B NSCLC. The secondary objectives were to estimate the overall and progressionfree survival. It was anticipated that esophagitis would be the primary dose limiting toxicity (DLT), and the study was designed to stop if the rate of grade 4 esophagitis was statistically shown to be Ն10% at ␣ ϭ 0.091. Accrual and continuous stopping rules were based on the primary DLT, grade 4 esophagitis, and were as follows: 2 primary DLTs in the first 3 subjects, 3 primary DLTs in the first 8 subjects, 4 primary DLTs in the first 14 patients, and 5 primary DLTs in the entire cohort (n ϭ 20). Assuming a 20 to 30% nonevaluable rate, 24 to 26 patients were required. In addition to the stopping rules related to the primary DLT, there was an additional stopping rule related to the failure to complete protocol therapy: If Ͼ50% of patients who initiate treatment had treatment delays of Ͼ2 weeks or did not complete treatment due to toxicity, the trial would be stopped and reviewed. Other grade 4 nonhematologic toxicities were evaluated during and for up to 90 days after initiation the concurrent chemoradiotherapy, and were used to monitor for excessive toxicity. The Kaplan-Meier (or product limit) method was used to estimate the time to event functions of progression-free survival and overall survival. Progressionfree survival has been defined as the time between the date of the start of treatment to disease progression or death (which ever occurs first) or the date of last contact. Overall survival has been defined as the time from the date of the start of treatment to the date of death or the date of last contact. Exact 95% confidence intervals were calculated for reported proportions (or percentages) of interest. Statistical analyses were performed with SAS statistical software, Versions 9.1, SAS Institute Inc., Cary, NC. An analysis of molecular studies will be provided in a separate article.
RESULTS
Patient Characteristics
Between March 2004 and January 2006, 24 patients were enrolled on the trial, and one withdrew informed consent before initiating therapy. Twenty-three received treatment on the trial, and the demographic data are presented on One patient experienced a grade 4 hypersensitivity reaction related to paclitaxel and did not continue treatment on the trial, and one patient received one cycle of induction therapy on the trial and was subsequently found to be ineligible; 21 patients started and were considered evaluable for assessing the tolerability and toxicity of concurrent chemoradiotherapy in combination with gefitinib.
Induction Chemotherapy
Twenty-three patients received at least one treatment of CIP induction chemotherapy, and 43 cycles were given. The hematologic and nonhematologic toxicities are shown in Table 2 . In general, the hematologic toxicities with induction CIP with pegfilgrastim supportive therapy were mild and acceptable. Only 2% of cycles were complicated by grade 3 or 4 neutropenia. The primary grade 3 or 4 nonhematologic toxicities were nausea, vomiting, and diarrhea, each of which complicated 7% of all cycles. Twenty-one patients were evaluable for response to induction CIP. Five patients had a partial response (response rate of 24%, 95% confidence interval [CI]: 8 -47%), and the remaining 16 patients had stable disease (stable disease rate of 76%, 95% CI: 53-92%). Of note, no patients experienced disease progression during the first two cycles. The median prechemotherapy GTV was 98 mL (range, 6 -305 mL), and the median postchemotherapy GTV was 64 mL (range, 6 -215 mL). This represents a reduction in the median GTV of 35%.
Concurrent Chemoradiation Toxicity
Twenty-one patients initiated the concurrent chemoradiation, and 20 patients completed therapy. One patient developed a pulmonary embolism and became supratherapeutic on anticoagulation and developed a hemorrhagic pericardial effusion and did not complete the concurrent chemoradiotherapy to 74 Gy. The primary toxicities were grade 3 esophagitis (19.5%), and cardiac arrhythmia due to atrial fibrillation (9.5%) ( Table 3) . Twelve patients initiated the maintenance gefitinib before the amendment, and patients received a median of 2 months of maintenance gefitinib (range, 1-4 months). Three patients developed late complications, defined as developing or persisting Ͼ60 days after completion of radiation therapy (grade 3 esophageal [n ϭ 2]; grade 3 anterior spinal cord syndrome due to probable spinal cord infarct [n ϭ 1]) within the radiation field. The patient presented with anterior spinal cord syndrome 8 months after completion 3-dimensional TCRT and 2 weeks after discontinuing gefitinib. She presented with symptoms of lower extremities weakness and tingling for 1 to 2 months and new onset urinary retention. The patient received radiation therapy dose at the maximum point of 4708 cGy from the APPA fields, and the total delivered including the scatter dose from the oblique fields was 4957 cGy. The patient was evaluated with magnetic resonance imaging of the spine, which was negative for cord compression, a lumbar puncture, which was negative for malignant cells, B12 and folate were within normal limits, and rapid plasma regain and hypercoaguable work-up was negative.
Progression-Free and Overall Survival
Of a total of 23 patients who had been followed for survival information, 19 have died and 4 were still alive at the time of analysis (Figure 1 
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( Figure 2 ). Median progression-free survival time was 9 months (95% CI: 7-13 months), and median overall survival time was 16 months (95% CI: 10 -20 months). Three patients experienced local progression, one patient experienced local and distant progression, and 11 patients experienced distant progression.
DISCUSSION
This trial did meet the primary end-point of demonstrating that gefitinib can safely be integrated into combined modality therapy without excessive toxicity or a significant number of patients failing to complete the prescribed treatment. However, the median survival time was disappointing in comparison to our previous trial and the recent trials that have used a similar treatment paradigm (Table 4) . 5, [22] [23] [24] [25] A recent retrospective analysis of patients (n ϭ 112) treated on 4 of our phase I/II or II combined revealed a median survival of 24 months (95% CI: 18 -31 months) and 5-year survival rate of 24% (95% CI: 16 -33%). 26 The increased use of PET scans (91% of patients) alone on this trial should have in improved survival due to superior staging techniques in comparison to our previous trials. The eligibility criteria are similar to our previous trials, which should have reduced the chance of any significant differences in the patient population on this trial from our previous trials. However, other unrecognized prognostic factors or changes in physician patient selection may have influenced enrollment and contributed the lower than expected survival, especially given the relatively small size of the trial. Of note, 4 of the 23 enrolled on this trial had Ն5% weight loss, which has been identified as a poor prognostic factor in combined modality trials. 24 Importantly, this trial differs from standard therapy is several aspects: the use of a more aggressive three drug induction therapy, the use of pegfilgastrim supportive therapy, increased dose of TCRT (74 Gy while the standard dose was 60 Gy), and the use of gefitinib concurrent with TCRT. It is difficult to determine whether one or a combination of these factors may have adversely impacted the survival.
One concern is that the treatment with gefitinib adversely impacted the survival of patients on this trial. At the same time, this trial was being performed SWOG, Cancer and Leukemia Group B (CALGB), and Australian centers were performing trials with gefitinib in combination combined modality therapy (Table 5) . [27] [28] [29] Patients on the SWOG trial were treated with concurrent chemoradiotherapy and consolidation docetaxel, and were then randomized to maintenance gefitinib (n ϭ 118) or placebo (n ϭ 125). With a median follow-up of 27 months patients randomized to the gefitinib arm had a worse overall survival than the placebo arm: overall survival from time of randomization 23 versus 35 months, respectively (p ϭ 0.01). The primary cause of the poor survival on the gefitinib arm was an excessive number of deaths due to progressive disease. There did not appear to be any difference in the baseline characteristics between the two treatment arms at time of randomization. On our trial, only 12 patients of the 23 patients received maintenance gefitinib for a median of 2 months (range, 1-4 months); thus, it is difficult to determine whether maintenance gefitinib contributed to the disappointing survival on our trial. The CALGB trial was a phase II trial with two cohorts, and patients were stratified based on clinical characteristics (stratum 1 and 2). 27 This trial was closed after the interim results of SWOG 0023 were announced. The patients on stratum 2 (n ϭ 39) were a similar patient population and received a similar treatment to the patients on our trial; the median progression-free survival was 9.2 months, 1-year survival rate was 47%, and median overall survival was 12 months. An Australian multicenter phase I trial investigated the combination of thoracic radiation therapy (60 Gy) and gefitinib 250 mg daily with carboplatin (AUC ϭ 2) weekly in the first cohort, and gefitinib 250 mg daily, carboplatin (AUC ϭ 2) weekly and escalating doses of paclitaxel (25, 25 , 45 mg/m 2 ) weekly on cohorts 2, 3, and 4, respectively. 29 All patients were required to have stage III disease, good functional status, and weight loss Ͻ10%. No dose-limiting toxicities were observed, and all patients received 60 Gy. A total of 28 patients were enrolled, and the fourth cohort (gefitinib 250 mg daily, carboplatin (AUC ϭ 2) weekly, and paclitaxel 45 mg/m 2 weekly) was expanded (n ϭ 16). The median survival for all patients on the trial has not been reached, and the 2-year survival rate is 60% (95% CI: 39 -82%).
The increased number of cancer deaths seen on the SWOG trial and the relatively low median survival times on our and the CALGB trials is concerning. The combination of treatment with radiation therapy and concurrent gefitinib or subsequent gefitinib may fundamentally alter the biology of the NSCLC. Several groups have demonstrated the development of "acquired resistance" due to the development of a secondary mutation resulting in threonine to methionine at 790 (T790M) of EGFR. 30 -32 This mutation has been reported to be present at the time of diagnosis in some patients as well. 33 Preclinical and anecdotal clinical evidence indicates that tumors with this mutation may have a more aggressive behavior. 34, 35 Focal amplification of the MET proto-oncogene has also been detected in lung cancer specimens from patients who were initially demonstrated a partial response to gefitinib or erlotinib and subsequently developed resistance. 36 The amplification the MET gene caused activation of the HER3-dependent intracellular pathways leading to the resistance. These changes and potentially other molecular changes related to the treatment may have altered the clinical course or the effectiveness of subsequent therapies of NSCLC in patients on this trial.
Preclinical models have investigated EGFR-TKI and the anti-EGRR monoclonal antibody C225 therapy in combination with radiation. 37, 38 Treatment with the C225 alone and in combination with radiation therapy resulted in a significant prolongation of tumor growth delay and local control in comparison to control tumors. Treatment with EGFR-TKI resulted in reduction of tumor volume, but did not improve local control in comparison to control tumors. This preclinical data suggests that anti-EGFR antibody direct therapy may be more effective in combination with radiation therapy than EGFR-TKI therapy in combination with radiation therapy. The Radiation Therapy Oncology Group recently performed a phase II trial of cetuximab (C225) in combination with weekly carboplatin (AUC ϭ 2) and paclitaxel (45 mg/m 2 ), followed by two cycles of carboplatin (AUC ϭ 6) and paclitaxel (200 mg/m 2 ) every 3 weeks. 39 Ninety-three patients have been enrolled and 87 are evaluable, and median follow-up of 17.6 months. The 18-month overall survival is 54.7%, and the primary toxicities were grade 4 hematologic toxicities and grade 3 esophagitis. Further follow-up and additional trials will be required to deter- Our current trial did use the treatment paradigm of induction chemotherapy, and the recent CALGB trial 39801 revealed a similar survival between concurrent chemoradiotherapy and induction chemotherapy followed by concurrent chemoradiotherapy (Table 4) . 24 The survival on both treatment arms was lower than the survival seen on the previous CALGB trial and other trials that employed induction chemotherapy. It is possible that as concurrent chemoradiotherapy within the United States has been become more widely accepted the patient population enrolled on stage III clinical trials has expanded to include patients who physicians previously would not have considered for this treatment paradigm, and this contributed to the lower survival than previous trials. The inclusion of patients with significant weight loss may have adversely impacted the overall survival results of this trial; 17% of patients enrolled on this trial had 5 to 10% weight loss, and 9% had Ͼ10% weight loss. Patients who had weight loss Ͼ5% and who were otherwise eligible (n ϭ 87) on the concurrent chemoradiotherapy and induction chemotherapy and concurrent chemoradiotherapy arms had a median survival of 8 and 10 months, respectively, and 3-year survival rate of 10% and 23%, respectively. The prevalence of patients with significant weight loss may significantly influence the outcome of small phase II trials of combined modality therapy.
Recent meta-analyses in the advanced NSCLC revealed that cisplastin-based treatments have a superior overall survival, but a higher rate of toxicity when compared to carboplatin-based treatments. 40, 41 In stage III disease, the use of cisplatin-based therapy may provide more effective treatment for occult micrometastatic disease. The Hoosier Oncology Group recently performed a phase III trial in which patients received cisplatin and etoposide and thoracic radiation therapy to 59.4 Gy, followed by randomization to consolidation docetaxel versus observation. 42 The median survival for all patients was 21 months, and there was no significant difference in the median survival between the observation and consolidation chemotherapy arm (24.2 versus 21.6 months, respectively; p ϭ 0.94). The numerically longer survival on the Hoosier Oncology Group than on CALGB 39801, the potential advantages of concurrent systemic therapy with thoracic radiation, and the data from meta-analyses from advanced stage disease raises the possibility that cisplatinbased treatment paradigms may be superior in stage III disease. A phase III trial specifically designed to compare cisplatin-based and carboplatin-based therapy would be required to definitively investigate this clinical question.
CONCLUSION
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by concurrent carboplatin, paclitaxel, and gefitinib and 3-dimensional TCRT to 74 Gy is feasible with an acceptable toxicity profile. However, the survival on this trial was disappointing in comparison to the survival seen on our previous trials.
